CY1118921T1 - Φαρμακευτικο παρασκευασμα που περιεχει οξυκωδονη και ναλοξονη - Google Patents
Φαρμακευτικο παρασκευασμα που περιεχει οξυκωδονη και ναλοξονηInfo
- Publication number
- CY1118921T1 CY1118921T1 CY20171100165T CY171100165T CY1118921T1 CY 1118921 T1 CY1118921 T1 CY 1118921T1 CY 20171100165 T CY20171100165 T CY 20171100165T CY 171100165 T CY171100165 T CY 171100165T CY 1118921 T1 CY1118921 T1 CY 1118921T1
- Authority
- CY
- Cyprus
- Prior art keywords
- naloxone
- pharmaceutical preparation
- preparation containing
- containing oxycodone
- oxycodone
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medical Treatment And Welfare Office Work (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Η εφεύρεση αφορά ένα σταθερό σε αποθήκευση φαρμακευτικό παρασκεύασμα που περιλαμβάνει οξυκωδόνη και ναλοξόνη για χρήση στην θεραπεία πόνου, με τις δραστικές ενώσεις να απελευθερώνονται από το παρασκεύασμα με παρατεταμένο, αμετάβλητο και ανεξάρτητο τρόπο.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10215131A DE10215131A1 (de) | 2002-04-05 | 2002-04-05 | Matrix zur verzögerten, gleichbleibenden und unabhängigen Freisetzung von Wirkstoffen |
DE10215067A DE10215067A1 (de) | 2002-04-05 | 2002-04-05 | Lagerstabiles pharmazeutisches Präparat, das Oxycodon und Naloxon umfasst |
EP03720424.5A EP1492505B1 (en) | 2002-04-05 | 2003-04-04 | Pharmaceutical preparation containing oxycodone and naloxone |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1118921T1 true CY1118921T1 (el) | 2018-01-10 |
Family
ID=28676052
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20091100346T CY1108914T1 (el) | 2002-04-05 | 2009-03-23 | Μητρα για παρατεταμενη, αμεταβλητη και ανεξαρτητη απελευθερωση δραστικων ενωσεων |
CY20151100735T CY1116640T1 (el) | 2002-04-05 | 2015-08-25 | Φαρμακευτικο παρασκευασμα που περιεχει οξυκωδονη και ναλοξονη |
CY20171100165T CY1118921T1 (el) | 2002-04-05 | 2017-02-07 | Φαρμακευτικο παρασκευασμα που περιεχει οξυκωδονη και ναλοξονη |
CY20171100665T CY1119120T1 (el) | 2002-04-05 | 2017-06-22 | Φαρμακευτικο παρασκευασμα που περιεχει οξυκωδονη και ναλοξονη |
CY20171100683T CY1119168T1 (el) | 2002-04-05 | 2017-06-28 | Φαρμακευτικο παρασκευασμα που περιεχει οξυκωδονη και ναλοξονη |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20091100346T CY1108914T1 (el) | 2002-04-05 | 2009-03-23 | Μητρα για παρατεταμενη, αμεταβλητη και ανεξαρτητη απελευθερωση δραστικων ενωσεων |
CY20151100735T CY1116640T1 (el) | 2002-04-05 | 2015-08-25 | Φαρμακευτικο παρασκευασμα που περιεχει οξυκωδονη και ναλοξονη |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20171100665T CY1119120T1 (el) | 2002-04-05 | 2017-06-22 | Φαρμακευτικο παρασκευασμα που περιεχει οξυκωδονη και ναλοξονη |
CY20171100683T CY1119168T1 (el) | 2002-04-05 | 2017-06-28 | Φαρμακευτικο παρασκευασμα που περιεχει οξυκωδονη και ναλοξονη |
Country Status (33)
Country | Link |
---|---|
US (11) | US20050245556A1 (el) |
EP (17) | EP1492506B2 (el) |
JP (5) | JP4620355B2 (el) |
KR (3) | KR100784341B1 (el) |
CN (4) | CN100411611C (el) |
AP (2) | AP2397A (el) |
AR (3) | AR039378A1 (el) |
AT (1) | ATE418967T2 (el) |
AU (2) | AU2003224041B2 (el) |
BR (2) | BR0309004A (el) |
CA (3) | CA2478523A1 (el) |
CO (2) | CO5611100A2 (el) |
CY (5) | CY1108914T1 (el) |
DE (6) | DE17169621T1 (el) |
DK (6) | DK1492506T4 (el) |
ES (7) | ES2733051T1 (el) |
FI (1) | FI7846U1 (el) |
GE (3) | GEP20064022B (el) |
HK (5) | HK1166463A1 (el) |
HU (4) | HUE031668T2 (el) |
IL (5) | IL163990A0 (el) |
LT (3) | LT2425821T (el) |
MA (2) | MA27116A1 (el) |
MX (2) | MXPA04009714A (el) |
NZ (1) | NZ535286A (el) |
PH (1) | PH12018000176A1 (el) |
PT (5) | PT2425821T (el) |
RU (3) | RU2295344C2 (el) |
SI (5) | SI2425824T1 (el) |
TN (1) | TNSN04192A1 (el) |
TW (3) | TWI334779B (el) |
WO (2) | WO2003084520A2 (el) |
ZA (2) | ZA200407267B (el) |
Families Citing this family (140)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2314893C (en) | 1997-12-22 | 2005-09-13 | Euro-Celtique, S.A. | Opioid agonist/antagonist combinations |
US6375957B1 (en) | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
RU2230556C2 (ru) | 1999-10-29 | 2004-06-20 | Эро-Селтик, С.А. | Препаративные формы гидрокодона с контролируемым высвобождением |
BR0108379A (pt) | 2000-02-08 | 2002-11-05 | Euro Celtique Sa | Composições de liberação controlada contendo agonista e antagonista opióide, método para a preparação de uma formulação em dosagem de analgésico opióide de liberação controlada com potência analgésica aumentada e sistema de administração através da derme para um analgésico opióide |
AUPQ899700A0 (en) | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
AU2002227383B2 (en) | 2000-10-30 | 2004-07-08 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
US20110104214A1 (en) | 2004-04-15 | 2011-05-05 | Purdue Pharma L.P. | Once-a-day oxycodone formulations |
DE60238756D1 (de) | 2001-05-11 | 2011-02-10 | Endo Pharmaceuticals Inc | Opioid enthaltende arzneiform gegen missbrauch |
AU2002316738B2 (en) | 2001-07-18 | 2009-01-08 | Euro-Celtique S.A. | Pharmaceutical combinations of oxycodone and naloxone |
HUP0401191A3 (en) | 2001-08-06 | 2006-11-28 | Euro Celtique Sa | Opioid agonist formulations with releasable and sequestered antagonist and process for their preparation |
EP1492506B2 (en) * | 2002-04-05 | 2016-06-29 | Euro-Celtique S.A. | Matrix for sustained, invariant and independent release of active compounds |
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
AR040682A1 (es) | 2002-07-25 | 2005-04-13 | Pharmacia Corp | Forma de dosificacion una vez al dia de pramipexol |
TWI347201B (en) | 2003-04-21 | 2011-08-21 | Euro Celtique Sa | Pharmaceutical products,uses thereof and methods for preparing the same |
DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
US8075872B2 (en) | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
JP4758897B2 (ja) * | 2003-09-25 | 2011-08-31 | ユーロ−セルティーク エス.エイ. | ヒドロコドンとナルトレキソンとの併用医薬 |
GB0403098D0 (en) | 2004-02-12 | 2004-03-17 | Euro Celtique Sa | Extrusion |
TWI350762B (en) * | 2004-02-12 | 2011-10-21 | Euro Celtique Sa | Particulates |
GB0501638D0 (en) * | 2005-01-28 | 2005-03-02 | Euro Celtique Sa | Particulates |
EP1604666A1 (en) | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD) |
EP1604667A1 (en) * | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioids for the treatment of the restless leg syndrome |
DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
CN101849921A (zh) | 2004-08-13 | 2010-10-06 | 贝林格尔·英格海姆国际有限公司 | 包含普拉克索或其可药用盐的延长释放片剂 |
JP4971159B2 (ja) | 2004-08-13 | 2012-07-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | プラミペキソール又はその薬学的に許容しうる塩を含有する徐放性ペレット製剤、その製法及び使用 |
AU2006208627B8 (en) | 2005-01-28 | 2009-08-13 | Mundipharma Pty Limited | Alcohol resistant dosage forms |
DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
EP1702558A1 (en) | 2005-02-28 | 2006-09-20 | Euro-Celtique S.A. | Method and device for the assessment of bowel function |
EP1695700A1 (en) * | 2005-02-28 | 2006-08-30 | Euro-Celtique S.A. | Dosage form containing oxycodone and naloxone |
EP1810678A1 (de) | 2006-01-19 | 2007-07-25 | Holger Lars Hermann | Verwendung einer Kombination von Morphin und Naloxon zur Drogensubstitution |
AU2011202866B2 (en) * | 2006-01-27 | 2012-06-14 | Mundipharma Pty Limited | Tamper resistant dosage forms |
EP1813276A1 (en) * | 2006-01-27 | 2007-08-01 | Euro-Celtique S.A. | Tamper resistant dosage forms |
US20080069891A1 (en) | 2006-09-15 | 2008-03-20 | Cima Labs, Inc. | Abuse resistant drug formulation |
DE202006018609U1 (de) * | 2006-08-29 | 2007-05-16 | Euro-Celtique S.A. | Verwendung von Opioidformulierungen in nadellosen Vorrichtungen zur Medikamentenverabreichung |
EP1897543A1 (en) | 2006-08-30 | 2008-03-12 | Euro-Celtique S.A. | Buprenorphine- wafer for drug substitution therapy |
US8445018B2 (en) | 2006-09-15 | 2013-05-21 | Cima Labs Inc. | Abuse resistant drug formulation |
US20080171762A1 (en) * | 2007-01-16 | 2008-07-17 | Ockert David M | Treatment of pain with naloxone |
DE102007011485A1 (de) * | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
CN101801350A (zh) * | 2007-08-13 | 2010-08-11 | 阿巴斯迪特宁医药有限公司 | 抗滥用药物、使用方法和制备方法 |
RU2007137044A (ru) * | 2007-10-05 | 2009-04-10 | Общество С Ограниченной Ответственностью "Концерн О3" (Ru) | Лекарственное средство, обладающее гемопоэзстимулирующим и гепатопротекторным действием |
CA2644179C (en) * | 2007-11-21 | 2018-09-25 | Pharmascience Inc. | Novel pharmaceutical composition comprising a disintegration matrix |
EP2249811A1 (en) | 2008-01-25 | 2010-11-17 | Grünenthal GmbH | Pharmaceutical dosage form |
EP2273983B1 (en) | 2008-05-09 | 2016-07-20 | Grünenthal GmbH | Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step |
CN105456267A (zh) * | 2008-07-07 | 2016-04-06 | 欧洲凯尔特公司 | 阿片类拮抗剂治疗尿潴留的用途 |
US9192578B2 (en) * | 2008-08-20 | 2015-11-24 | Board Of Regents, The University Of Texas System | Hot-melt extrusion of modified release multi-particulates |
HUE047438T2 (hu) | 2008-10-30 | 2020-04-28 | Gruenenthal Gmbh | Új és potens tapentadol dózisformák |
EP2381937A2 (en) | 2008-12-31 | 2011-11-02 | Upsher-Smith Laboratories, Inc. | Opioid-containing oral pharmaceutical compositions and methods |
MX347106B (es) * | 2009-03-10 | 2017-04-12 | Euro-Celtique S A * | Coposiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona. |
GB0909680D0 (en) * | 2009-06-05 | 2009-07-22 | Euro Celtique Sa | Dosage form |
PL2456424T3 (pl) | 2009-07-22 | 2013-12-31 | Gruenenthal Gmbh | Stabilizowana przed utlenianiem odporna na naruszenie postać dawkowania |
PL2456427T3 (pl) * | 2009-07-22 | 2015-07-31 | Gruenenthal Gmbh | Wytłaczana na gorąco postać dawki o kontrolowanym uwalnianiu |
US9023390B2 (en) | 2009-09-17 | 2015-05-05 | Upsher-Smith Laboratories, Inc. | Sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti-inflammatory drug |
US9125867B2 (en) * | 2010-02-24 | 2015-09-08 | Invincible Biotechnology | Diversion- and/or abuse-resistant compositions and methods for making the same |
EA201291211A1 (ru) | 2010-05-10 | 2013-05-30 | Эро-Селтик С.А. | Фармацевтические композиции, содержащие гидроморфон и налоксон |
CN103002882B (zh) | 2010-05-10 | 2016-03-02 | 欧洲凯尔特公司 | 不含活性剂之颗粒及包含其之片剂的制备 |
US9901540B2 (en) | 2010-05-10 | 2018-02-27 | Euro-Celtique S.A. | Combination of active loaded granules with additional actives |
JP2013526523A (ja) | 2010-05-11 | 2013-06-24 | シマ ラブス インク. | メトプロロールを含むアルコール耐性持続放出性経口剤形 |
KR20130098320A (ko) | 2010-08-04 | 2013-09-04 | 토마스 줄리어스 보로디 | 분변 세균총 이식을 위한 조성물, 그의 제조 방법과 사용 방법, 및 그를 전달하기 위한 장치 |
WO2012020097A2 (en) * | 2010-08-13 | 2012-02-16 | Euro-Celtique S.A. | Use of binders for manufacturing storage stable formulations |
AU2011297901B2 (en) | 2010-09-02 | 2014-07-31 | Grunenthal Gmbh | Tamper resistant dosage form comprising inorganic salt |
MX2013002293A (es) | 2010-09-02 | 2013-05-09 | Gruenenthal Gmbh | Forma de dosificacion resistente a alteracion que comprende un polimero anionico. |
ES2562643T5 (es) | 2010-09-30 | 2019-05-24 | Astrazeneca Ab | Conjugado de naloxol-peg cristalino |
MX355760B (es) | 2010-12-13 | 2018-04-27 | Salix Pharmaceuticals Inc | Formulaciones gástricas y colónicas y métodos para elaborar y usar las mismas. |
EP2683390B1 (en) | 2011-03-09 | 2017-05-03 | Regents Of The University Of Minnesota | Compositions and methods for transplantation of colon microbiota |
AT511581A1 (de) | 2011-05-26 | 2012-12-15 | G L Pharma Gmbh | Orale retardierende formulierung |
PE20141638A1 (es) | 2011-07-29 | 2014-11-22 | Gruenenthal Chemie | Tableta a prueba de manipulacion que proporciona liberacion de farmaco inmediato |
US20130028972A1 (en) | 2011-07-29 | 2013-01-31 | Grunenthal Gmbh | Tamper-resistant tablet providing immediate drug release |
EP2750858A2 (en) * | 2011-08-29 | 2014-07-09 | DSM IP Assets B.V. | Laboratory extruder and method for producing pharmaceutical products |
WO2013050539A2 (en) * | 2011-10-06 | 2013-04-11 | Grünenthal GmbH | Tamper-resistant oral pharmaceutical dosage form comprising opioid agonist and opioid antagonist |
KR20140096062A (ko) | 2011-11-17 | 2014-08-04 | 그뤼넨탈 게엠베하 | 약리학적 활성 성분, 오피오이드 길항제 및/또는 혐오제, 폴리알킬렌 옥사이드 및 음이온성 중합체를 포함하는 탬퍼-저항성 경구 약제학적 투여형 |
US20130225697A1 (en) | 2012-02-28 | 2013-08-29 | Grunenthal Gmbh | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
SG11201406025UA (en) | 2012-04-17 | 2014-11-27 | Purdue Pharma Lp | Systems and methods for treating an opioid-induced adverse pharmacodynamic response |
EA201401139A1 (ru) | 2012-04-18 | 2015-03-31 | Грюненталь Гмбх | Устойчивая к разрушению и к сбросу дозы фармацевтическая лекарственная форма |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
US9719144B2 (en) | 2012-05-25 | 2017-08-01 | Arizona Board Of Regents | Microbiome markers and therapies for autism spectrum disorders |
CN110170050A (zh) | 2012-06-04 | 2019-08-27 | 高拉夫·阿格拉沃尔 | 用于治疗克罗恩氏病和相关病况以及感染的组合物和方法 |
DK2877163T3 (en) | 2012-07-27 | 2019-04-15 | Redhill Biopharma Ltd | FORMULATIONS AND PROCEDURES FOR THE PREPARATION OF FORMS FOR USING GAS DRAINAGE |
US10485798B2 (en) | 2012-08-22 | 2019-11-26 | Aptapharma Inc. | Methylnaltrexone nasal formulations, methods of making, and use thereof |
EP2931279B1 (en) * | 2012-12-14 | 2024-03-20 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
US20140275038A1 (en) | 2013-03-15 | 2014-09-18 | Inspirion Delivery Technologies, Llc | Abuse deterrent compositions and methods of use |
US20160089363A1 (en) | 2013-04-30 | 2016-03-31 | Thomas Julius Borody | Compositions and methods for treating microbiota-related psychotropic conditions and diseases |
US20160244459A1 (en) | 2013-05-24 | 2016-08-25 | Rhodes Technologies | Opioid ketal compounds and uses thereof |
MX2015016254A (es) | 2013-05-29 | 2016-04-20 | Gruenenthal Gmbh | Forma de dosificacion resistente al uso indebido con perfil de liberacion bimodal. |
JP6445537B2 (ja) | 2013-05-29 | 2018-12-26 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 1個または複数の粒子を含有する改変防止(tamper−resistant)剤形 |
JP6449871B2 (ja) | 2013-07-12 | 2019-01-09 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | エチレン−酢酸ビニルポリマーを含有する改変防止剤形 |
CA2918004C (en) | 2013-07-23 | 2018-11-20 | Euro-Celtique S.A. | A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation |
CA2919892C (en) | 2013-08-12 | 2019-06-18 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
WO2015065547A1 (en) | 2013-10-31 | 2015-05-07 | Cima Labs Inc. | Immediate release abuse-deterrent granulated dosage forms |
KR102194174B1 (ko) | 2013-11-13 | 2020-12-23 | 유로-셀티큐 에스.에이. | 통증 및 오피오이드 장 기능장애 증후군의 치료를 위한 히드로모르폰 및 날록손 |
JP6480936B2 (ja) | 2013-11-26 | 2019-03-13 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | クライオミリングによる粉末状医薬組成物の調製 |
WO2015086528A1 (de) | 2013-12-11 | 2015-06-18 | Develco Pharma Schweiz Ag | Naloxon-monopräparat und mehrschichttablette |
US10105360B2 (en) | 2013-12-11 | 2018-10-23 | Develco Pharma Schweiz Ag | Method and composition for the treatment of opioid induced constipation |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
WO2015095391A1 (en) | 2013-12-17 | 2015-06-25 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
CA2875384A1 (en) | 2013-12-20 | 2015-06-20 | AntiOP, Inc. | Intranasal naloxone compositions and methods of making and using same |
US10085937B2 (en) | 2014-03-14 | 2018-10-02 | Adapt Pharma Limited | Nasal drug products and methods of their use |
US9561177B2 (en) | 2014-03-14 | 2017-02-07 | Adapt Pharma Limited | Nasal drug products and methods of their use |
US9480644B2 (en) | 2014-03-14 | 2016-11-01 | Opiant Pharmaceuticals, Inc. | Nasal drug products and methods of their use |
RU2020112530A (ru) | 2014-03-14 | 2021-07-21 | ОПИАНТ ФАРМАСЮТИКАЛС, Инк. | Назальные готовые лекарственные формы и способы их применения |
WO2015173195A1 (en) | 2014-05-12 | 2015-11-19 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
EP3148512A1 (en) | 2014-05-26 | 2017-04-05 | Grünenthal GmbH | Multiparticles safeguarded against ethanolic dose-dumping |
US9707184B2 (en) | 2014-07-17 | 2017-07-18 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
US10729685B2 (en) | 2014-09-15 | 2020-08-04 | Ohemo Life Sciences Inc. | Orally administrable compositions and methods of deterring abuse by intranasal administration |
US9849124B2 (en) | 2014-10-17 | 2017-12-26 | Purdue Pharma L.P. | Systems and methods for treating an opioid-induced adverse pharmacodynamic response |
EP3209282A4 (en) | 2014-10-20 | 2018-05-23 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
EP3229785A2 (de) * | 2014-12-08 | 2017-10-18 | Develco Pharma Schweiz AG | Naloxon-monopräparat und mehrschichttablette |
WO2016170097A1 (en) | 2015-04-24 | 2016-10-27 | Grünenthal GmbH | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
EP3294307A4 (en) | 2015-05-14 | 2019-01-23 | Crestovo Holdings Llc | COMPOSITIONS FOR TRANSPLANTATION OF FECAL FLORA AND METHODS OF PREPARATION AND USE THEREOF, AND DEVICES FOR THEIR ADMINISTRATION |
NZ776366A (en) | 2015-05-22 | 2023-02-24 | Univ Minnesota | Methods for treating autism spectrum disorder and associated symptoms |
JP2018526414A (ja) | 2015-09-10 | 2018-09-13 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護 |
EP3352773A4 (en) | 2015-09-24 | 2019-03-27 | San Diego State University (SDSU) Foundation DBA San Diego State University Research Foundation | ANTIBACTERIAL AND PROTECTIVE BACTERIOPHAGE FORMULATIONS AND PROCESS FOR THE PREPARATION AND USE THEREOF |
US9943513B1 (en) | 2015-10-07 | 2018-04-17 | Banner Life Sciences Llc | Opioid abuse deterrent dosage forms |
EP3435984A4 (en) * | 2016-03-31 | 2019-11-06 | SpecGx LLC | MISUSE OF INFACTIOUS PHARMACEUTICAL FORMATION WITH DELAYED RELEASE |
US10335405B1 (en) | 2016-05-04 | 2019-07-02 | Patheon Softgels, Inc. | Non-burst releasing pharmaceutical composition |
US20170360848A1 (en) | 2016-06-15 | 2017-12-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for treating autism spectrum disorder and associated symptoms |
US10849936B2 (en) | 2016-07-01 | 2020-12-01 | Regents Of The University Of Minnesota | Compositions and methods for C. difficile treatment |
US20180036352A1 (en) | 2016-08-03 | 2018-02-08 | Crestovo Holdings Llc | Methods for treating ulcerative colitis |
EP3290027A1 (en) * | 2016-09-02 | 2018-03-07 | Develco Pharma Schweiz AG | Method and composition for the treatment of opioid induced constipation |
US10092601B2 (en) | 2016-10-11 | 2018-10-09 | Crestovo Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
US11213549B2 (en) | 2016-10-11 | 2022-01-04 | Finch Therapeutics Holdings Llc | Compositions and method for treating primary sclerosing cholangitis and related disorders |
WO2018071537A1 (en) | 2016-10-11 | 2018-04-19 | Crestovo Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
WO2018187464A1 (en) | 2017-04-05 | 2018-10-11 | Crestovo Holdings Llc | Compositions and methods for treating diverticulitis and related disorders |
AU2018250206A1 (en) | 2017-04-05 | 2019-10-31 | Crestovo Holdings Llc | Compositions and methods for treating parkinson's disease (PD) and related disorders |
AU2018272048B2 (en) | 2017-05-26 | 2024-04-04 | Finch Therapeutics Holdings Llc | Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same |
US10335375B2 (en) | 2017-05-30 | 2019-07-02 | Patheon Softgels, Inc. | Anti-overingestion abuse deterrent compositions |
EP3664823B1 (en) | 2017-08-07 | 2024-06-05 | Finch Therapeutics Holdings LLC | Composition for use in preventing or treating an enterococcal blood stream infection |
WO2019152002A1 (en) * | 2018-01-31 | 2019-08-08 | Dharma Laboratories LLC | Non-extractable oral solid dosage forms |
US10624856B2 (en) | 2018-01-31 | 2020-04-21 | Dharma Laboratories LLC | Non-extractable oral solid dosage forms |
EP3755704A1 (en) | 2018-02-23 | 2020-12-30 | Rhodes Technologies Inc. | Novel opioid compounds and uses thereof |
US11166990B2 (en) | 2018-07-13 | 2021-11-09 | Finch Therapeutics Holdings Llc | Methods and compositions for treating ulcerative colitis |
EP3826635A4 (en) | 2018-07-23 | 2022-04-27 | Trevi Therapeutics, Inc. | TREATMENT OF CHRONIC COUGH, DIFFICULT BREATHING AND DYSPNEA |
CA3114423A1 (en) | 2018-09-27 | 2020-04-02 | Finch Therapeutics Holdings Llc | Compositions and methods for treating epilepsy and related disorders |
US20220062200A1 (en) | 2019-05-07 | 2022-03-03 | Clexio Biosciences Ltd. | Abuse-deterrent dosage forms containing esketamine |
WO2020225773A1 (en) | 2019-05-07 | 2020-11-12 | Clexio Biosciences Ltd. | Abuse-deterrent dosage forms containing esketamine |
Family Cites Families (278)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2770569A (en) | 1952-08-01 | 1956-11-13 | Hoffmann La Roche | Analgesic compositions |
US3173877A (en) | 1957-09-09 | 1965-03-16 | Wyandotte Chemicals Corp | Detergent compositions comprising inorganic esters of epoxyhydrocarbon polymers |
US3173876A (en) * | 1960-05-27 | 1965-03-16 | John C Zobrist | Cleaning methods and compositions |
NL271831A (el) * | 1960-11-29 | |||
US3493657A (en) | 1961-03-14 | 1970-02-03 | Mozes Juda Lewenstein | Therapeutic compositions of n-allyl-14-hydroxy - dihydronormorphinane and morphine |
US3332950A (en) | 1963-03-23 | 1967-07-25 | Endo Lab | 14-hydroxydihydronormorphinone derivatives |
US3276586A (en) * | 1963-08-30 | 1966-10-04 | Rosaen Filter Co | Indicating means for fluid filters |
NL6714885A (el) * | 1967-11-02 | 1969-05-06 | ||
US3541006A (en) * | 1968-07-03 | 1970-11-17 | Amicon Corp | Ultrafiltration process |
US3541005A (en) * | 1969-02-05 | 1970-11-17 | Amicon Corp | Continuous ultrafiltration of macromolecular solutions |
US3773955A (en) | 1970-08-03 | 1973-11-20 | Bristol Myers Co | Analgetic compositions |
US3879555A (en) | 1970-11-16 | 1975-04-22 | Bristol Myers Co | Method of treating drug addicts |
US3676557A (en) | 1971-03-02 | 1972-07-11 | Endo Lab | Long-acting narcotic antagonist formulations |
GB1390772A (en) * | 1971-05-07 | 1975-04-16 | Endo Lab | Oral narcotic composition |
FR2183546B1 (el) * | 1972-05-10 | 1975-06-20 | Servier Lab | |
US3965256A (en) | 1972-05-16 | 1976-06-22 | Synergistics | Slow release pharmaceutical compositions |
US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US3916889A (en) * | 1973-09-28 | 1975-11-04 | Sandoz Ag | Patient ventilator apparatus |
US3966940A (en) | 1973-11-09 | 1976-06-29 | Bristol-Myers Company | Analgetic compositions |
GB1478759A (en) * | 1974-11-18 | 1977-07-06 | Alza Corp | Process for forming outlet passageways in pills using a laser |
US3966040A (en) * | 1975-03-05 | 1976-06-29 | Hazelwood John E | Combined vibratory feeder drive unit, vibratory feeder bowl, and parts separator |
US4077407A (en) * | 1975-11-24 | 1978-03-07 | Alza Corporation | Osmotic devices having composite walls |
US4126684A (en) * | 1976-02-11 | 1978-11-21 | Ciba-Geigy Corporation | 4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse |
US4063064A (en) * | 1976-02-23 | 1977-12-13 | Coherent Radiation | Apparatus for tracking moving workpiece by a laser beam |
LU77339A1 (el) | 1977-05-16 | 1979-01-19 | ||
US4176186A (en) | 1978-07-28 | 1979-11-27 | Boehringer Ingelheim Gmbh | Quaternary derivatives of noroxymorphone which relieve intestinal immobility |
US4200098A (en) * | 1978-10-23 | 1980-04-29 | Alza Corporation | Osmotic system with distribution zone for dispensing beneficial agent |
US4285987A (en) * | 1978-10-23 | 1981-08-25 | Alza Corporation | Process for manufacturing device with dispersion zone |
US4237140A (en) | 1979-05-18 | 1980-12-02 | E. I. Du Pont De Nemours And Company | Analgesic mixture of nalbuphine and acetaminophen |
US4293539A (en) | 1979-09-12 | 1981-10-06 | Eli Lilly And Company | Controlled release formulations and method of treatment |
IE49324B1 (en) | 1979-12-19 | 1985-09-18 | Euro Celtique Sa | Controlled release compositions |
US4457933A (en) * | 1980-01-24 | 1984-07-03 | Bristol-Myers Company | Prevention of analgesic abuse |
US4464378A (en) | 1981-04-28 | 1984-08-07 | University Of Kentucky Research Foundation | Method of administering narcotic antagonists and analgesics and novel dosage forms containing same |
US4401672A (en) | 1981-10-13 | 1983-08-30 | Regents Of The University Of Minnesota | Non-addictive narcotic antitussive preparation |
US4608376A (en) | 1981-10-16 | 1986-08-26 | Carolyn McGinnis | Opiate agonists and antagonists |
WO1983003197A1 (en) | 1982-03-16 | 1983-09-29 | Univ Rockefeller | Method for controlling gastrointestinal dysmotility |
US4987136A (en) | 1982-03-16 | 1991-01-22 | The Rockefeller University | Method for controlling gastrointestinal dysmotility |
US4443428A (en) | 1982-06-21 | 1984-04-17 | Euroceltique, S.A. | Extended action controlled release compositions |
US4451470A (en) | 1982-07-06 | 1984-05-29 | E. I. Du Pont De Nemours And Company | Analgesic, antagonist, and/or anorectic 14-fluoromorphinans |
US4803208A (en) | 1982-09-30 | 1989-02-07 | Sloan-Kettering Institute For Cancer Research | Opiate agonists and antagonists |
GB8332556D0 (en) * | 1983-12-06 | 1984-01-11 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
US5266574A (en) | 1984-04-09 | 1993-11-30 | Ian S. Zagon | Growth regulation and related applications of opioid antagonists |
US4668685A (en) * | 1984-07-05 | 1987-05-26 | E.I. Du Pont De Nemours And Company | Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists |
US4626539A (en) * | 1984-08-10 | 1986-12-02 | E. I. Dupont De Nemours And Company | Trandermal delivery of opioids |
DE3434946A1 (de) | 1984-09-22 | 1986-04-03 | Basf Ag, 6700 Ludwigshafen | Diarylacetylene, ihre herstellung und verwendung |
US4573995A (en) | 1984-10-09 | 1986-03-04 | Alza Corporation | Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine |
GB8430346D0 (en) | 1984-11-30 | 1985-01-09 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
US4806341A (en) | 1985-02-25 | 1989-02-21 | Rutgers, The State University Of New Jersey | Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration |
ZA861211B (en) | 1985-02-25 | 1987-10-28 | Lilly Co Eli | Analgesic composition |
JPS61280423A (ja) | 1985-06-05 | 1986-12-11 | Kiyuukiyuu Yakuhin Kogyo Kk | 口腔内粘膜貼付剤 |
GB8514665D0 (en) | 1985-06-11 | 1985-07-10 | Eroceltique Sa | Oral pharmaceutical composition |
FR2585246A1 (fr) | 1985-07-26 | 1987-01-30 | Cortial | Procede d'obtention de formes pharmaceutiques solides a liberation prolongee |
GB8521350D0 (en) | 1985-08-28 | 1985-10-02 | Euro Celtique Sa | Analgesic composition |
JPS63500799A (ja) | 1985-09-06 | 1988-03-24 | ベーカー・カミンス・ファーマシューティカルス・インコーポレーテッド | 持続性オピオイド拮抗作用を得るための方法および組成物 |
US4760069A (en) | 1985-09-23 | 1988-07-26 | Nova Pharmaceutical Corporation | Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists |
US4889860A (en) | 1985-09-23 | 1989-12-26 | Nova Pharmaceutical Corporation | Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists |
US4722928A (en) | 1985-12-02 | 1988-02-02 | E. I. Du Pont De Nemours And Company | N-oxide prodrug derivatives of 3-hydroxy morphinans and partial morphinans having improved oral bioavailability, pharmaceutical compositions, and processes |
US4730048A (en) | 1985-12-12 | 1988-03-08 | Regents Of The University Of Minnesota | Gut-selective opiates |
US4861781A (en) | 1986-03-07 | 1989-08-29 | The University Of Chicago | Quaternary derivatives of noroxymorphone which relieve nausea and emesis |
US4719215A (en) | 1986-03-07 | 1988-01-12 | University Of Chicago | Quaternary derivatives of noroxymorphone which relieve nausea and emesis |
US5316759A (en) | 1986-03-17 | 1994-05-31 | Robert J. Schaap | Agonist-antagonist combination to reduce the use of nicotine and other drugs |
GB8613689D0 (en) | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
GB8613688D0 (en) | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
EP0249347B1 (en) | 1986-06-10 | 1994-06-29 | Euroceltique S.A. | Controlled release dihydrocodeine composition |
US4785000A (en) | 1986-06-18 | 1988-11-15 | The Rockefeller University | Method of treating patients suffering from chronic pain or chronic cough |
US4769372A (en) | 1986-06-18 | 1988-09-06 | The Rockefeller University | Method of treating patients suffering from chronic pain or chronic cough |
US4970075A (en) | 1986-07-18 | 1990-11-13 | Euroceltique, S.A. | Controlled release bases for pharmaceuticals |
US4861598A (en) * | 1986-07-18 | 1989-08-29 | Euroceltique, S.A. | Controlled release bases for pharmaceuticals |
US5356900A (en) | 1986-10-07 | 1994-10-18 | Bernard Bihari | Method of treating chronic herpes virus infections using an opiate receptor antagonist |
GB8626098D0 (en) | 1986-10-31 | 1986-12-03 | Euro Celtique Sa | Controlled release hydromorphone composition |
US4806543A (en) | 1986-11-25 | 1989-02-21 | Board Of Trustees Of The Leland Stanford Junior University | Method and compositions for reducing neurotoxic injury |
GB8628728D0 (en) | 1986-12-02 | 1987-01-07 | Euro Celtique Sa | Spheroids |
GB8705083D0 (en) | 1987-03-04 | 1987-04-08 | Euro Celtique Sa | Spheroids |
GB8728294D0 (en) | 1987-12-03 | 1988-01-06 | Reckitt & Colmann Prod Ltd | Treatment compositions |
DE3812567A1 (de) * | 1988-04-15 | 1989-10-26 | Basf Ag | Verfahren zur herstellung pharmazeutischer mischungen |
US4873076A (en) | 1988-04-29 | 1989-10-10 | Baker Cummins Pharmaceuticals, Inc. | Method of safely providing anesthesia or conscious sedation |
GB8813064D0 (en) | 1988-06-02 | 1988-07-06 | Euro Celtique Sa | Controlled release dosage forms having defined water content |
US4882335A (en) | 1988-06-13 | 1989-11-21 | Alko Limited | Method for treating alcohol-drinking response |
EP0352361A1 (en) | 1988-07-29 | 1990-01-31 | The Rockefeller University | Method of treating patients suffering from chronic pain or chronic cough |
US5236714A (en) * | 1988-11-01 | 1993-08-17 | Alza Corporation | Abusable substance dosage form having reduced abuse potential |
CA2002492A1 (en) | 1988-11-11 | 1990-05-11 | Sandra T. A. Malkowska | Pharmaceutical ion exchange resin composition |
US5102887A (en) | 1989-02-17 | 1992-04-07 | Arch Development Corporation | Method for reducing emesis and nausea induced by the administration of an emesis causing agent |
US5096715A (en) | 1989-11-20 | 1992-03-17 | Alko Ltd. | Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist |
US5075341A (en) | 1989-12-01 | 1991-12-24 | The Mclean Hospital Corporation | Treatment for cocaine abuse |
US5086058A (en) | 1990-06-04 | 1992-02-04 | Alko Ltd. | Method for treating alcoholism with nalmefene |
FR2669336B1 (fr) | 1990-11-20 | 1993-01-22 | Adir | Nouveaux derives d'oxazolo pyridines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent. |
HU208633B (en) | 1991-02-04 | 1993-12-28 | Alkaloida Vegyeszeti Gyar | Process for production of analgetic compositions as applicable for blocking of opioid-binding spaces /2-receptors/ causing respiration depression |
US5486362A (en) | 1991-05-07 | 1996-01-23 | Dynagen, Inc. | Controlled, sustained release delivery system for treating drug dependency |
JP3178541B2 (ja) | 1991-05-29 | 2001-06-18 | キヤノン株式会社 | 画像処理方法及び装置 |
US5149538A (en) | 1991-06-14 | 1992-09-22 | Warner-Lambert Company | Misuse-resistive transdermal opioid dosage form |
GB9117361D0 (en) * | 1991-08-12 | 1991-09-25 | Euro Celtique Sa | Oral dosage form |
KR100221695B1 (ko) * | 1991-08-12 | 1999-09-15 | 그린 마틴, 브라이언 쥐 테슬리 | 약학적 구상 제형 |
KR100243956B1 (ko) | 1991-09-06 | 2000-03-02 | 랄프 알. 팔로 | 트라마돌 물질 및 아세트아미노펜을 포함하는 통증 치료용 약제학적 조성물 |
US5215758A (en) | 1991-09-11 | 1993-06-01 | Euroceltique, S.A. | Controlled release matrix suppository for pharmaceuticals |
US5225440A (en) | 1991-09-13 | 1993-07-06 | The United States Of America As Represented By The Department Of Health And Human Services | Attenuation of the opioid withdrawal syndrome by inhibitors of nitric oxide synthase |
US5266331A (en) | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
US5656295A (en) * | 1991-11-27 | 1997-08-12 | Euro-Celtique, S.A. | Controlled release oxycodone compositions |
US5681585A (en) * | 1991-12-24 | 1997-10-28 | Euro-Celtique, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
US5968551A (en) * | 1991-12-24 | 1999-10-19 | Purdue Pharma L.P. | Orally administrable opioid formulations having extended duration of effect |
US5286493A (en) * | 1992-01-27 | 1994-02-15 | Euroceltique, S.A. | Stabilized controlled release formulations having acrylic polymer coating |
US5958459A (en) | 1991-12-24 | 1999-09-28 | Purdue Pharma L.P. | Opioid formulations having extended controlled released |
US5478577A (en) * | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5472712A (en) * | 1991-12-24 | 1995-12-05 | Euroceltique, S.A. | Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
US5273760A (en) * | 1991-12-24 | 1993-12-28 | Euroceltigue, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
GB9203689D0 (en) | 1992-02-20 | 1992-04-08 | Euro Celtique Sa | Pharmaceutical composition |
GB9204354D0 (en) | 1992-02-28 | 1992-04-08 | Biokine Tech Ltd | Compounds for medicinal use |
JP3301024B2 (ja) | 1992-06-22 | 2002-07-15 | ザ・リージェンツ・オブ・ザ・ユニバーシテイ・オブ・カリフォルニア | グリシンレセプター拮抗物質及びその用途 |
US5352680A (en) | 1992-07-15 | 1994-10-04 | Regents Of The University Of Minnesota | Delta opioid receptor antagonists to block opioid agonist tolerance and dependence |
US5256669A (en) | 1992-08-07 | 1993-10-26 | Aminotek Sciences, Inc. | Methods and compositions for treating acute or chronic pain and drug addiction |
US5324351A (en) * | 1992-08-13 | 1994-06-28 | Euroceltique | Aqueous dispersions of zein and preparation thereof |
US6096756A (en) | 1992-09-21 | 2000-08-01 | Albert Einstein College Of Medicine Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
US5633259A (en) | 1992-09-21 | 1997-05-27 | United Biomedical, Inc. | Method for identification of low/non-addictive opioid analgesics and the use of said analgesics for treatment of opioid addiction |
US5472943A (en) | 1992-09-21 | 1995-12-05 | Albert Einstein College Of Medicine Of Yeshiva University, | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists |
US5580876A (en) | 1992-09-21 | 1996-12-03 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
US20010006967A1 (en) | 1992-09-21 | 2001-07-05 | Stanley M. Crain | Method of simultaneously enhancing analgesic potency and attenuating adverse side effects caused by tramadol and other bimodally-acting opioid agonists |
US5512578A (en) | 1992-09-21 | 1996-04-30 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists |
EP0668764A1 (en) | 1992-09-21 | 1995-08-30 | QIN, Bo-yi | Methods for identifying and using low/non-addictive opioid analgesics |
US5869097A (en) | 1992-11-02 | 1999-02-09 | Alza Corporation | Method of therapy comprising an osmotic caplet |
US5604260A (en) | 1992-12-11 | 1997-02-18 | Merck Frosst Canada Inc. | 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2 |
US5321012A (en) | 1993-01-28 | 1994-06-14 | Virginia Commonwealth University Medical College | Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance |
US5585348A (en) | 1993-02-10 | 1996-12-17 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Use of excitatory opioid receptor antagonists to prevent growth factor-induced hyperalgesia |
US5352683A (en) | 1993-03-05 | 1994-10-04 | Virginia Commonwealth University Medical College Of Virginia | Method for the treatment of chronic pain |
CA2115792C (en) | 1993-03-05 | 2005-11-01 | David J. Mayer | Method for the treatment of pain |
US5409944A (en) | 1993-03-12 | 1995-04-25 | Merck Frosst Canada, Inc. | Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase |
IL109460A (en) * | 1993-05-10 | 1998-03-10 | Euro Celtique Sa | Controlled release formulation comprising tramadol |
US5457208A (en) | 1993-06-21 | 1995-10-10 | Regents Of The University Of Minnesota | Kappa opioid receptor antagonists |
US5436265A (en) | 1993-11-12 | 1995-07-25 | Merck Frosst Canada, Inc. | 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents |
US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
CN1230154C (zh) * | 1993-07-01 | 2005-12-07 | 欧洲凯尔特公司 | 缓释组合物及制备药用组合物的方法 |
IL110014A (en) * | 1993-07-01 | 1999-11-30 | Euro Celtique Sa | Solid controlled-release oral dosage forms of opioid analgesics |
NZ260883A (en) | 1993-07-01 | 1997-06-24 | Euro Celtique Sa | Oral sustained-release medicaments containing morphine |
US5879705A (en) | 1993-07-27 | 1999-03-09 | Euro-Celtique S.A. | Sustained release compositions of morphine and a method of preparing pharmaceutical compositions |
DE4325465B4 (de) | 1993-07-29 | 2004-03-04 | Zenz, Michael, Prof. Dr.med. | Orales pharmazeutisches Präparat für die Schmerztherapie |
GB9319568D0 (en) | 1993-09-22 | 1993-11-10 | Euro Celtique Sa | Pharmaceutical compositions and usages |
EP0647448A1 (en) | 1993-10-07 | 1995-04-12 | Euroceltique S.A. | Orally administrable opioid formulations having extended duration of effect |
US6210714B1 (en) | 1993-11-23 | 2001-04-03 | Euro-Celtique S.A. | Immediate release tablet cores of acetaminophen having sustained-release coating |
US5500227A (en) | 1993-11-23 | 1996-03-19 | Euro-Celtique, S.A. | Immediate release tablet cores of insoluble drugs having sustained-release coating |
KR100354702B1 (ko) | 1993-11-23 | 2002-12-28 | 유로-셀티크 소시에떼 아노뉨 | 약학조성물의제조방법및서방형조성물 |
US5891471A (en) | 1993-11-23 | 1999-04-06 | Euro-Celtique, S.A. | Pharmaceutical multiparticulates |
EP0654263B1 (en) | 1993-11-23 | 2002-01-23 | Euro-Celtique S.A. | Method for preparing a sustained release composition |
US5834477A (en) | 1993-12-08 | 1998-11-10 | The United States Of America As Represented By The Secretary Of The Army | Opiate analgesic formulation with improved safety |
US5376662A (en) | 1993-12-08 | 1994-12-27 | Ockert; David M. | Method of attenuating nerve injury induced pain |
US5843480A (en) | 1994-03-14 | 1998-12-01 | Euro-Celtique, S.A. | Controlled release diamorphine formulation |
US5411745A (en) * | 1994-05-25 | 1995-05-02 | Euro-Celtique, S.A. | Powder-layered morphine sulfate formulations |
US6077533A (en) | 1994-05-25 | 2000-06-20 | Purdue Pharma L.P. | Powder-layered oral dosage forms |
US5958458A (en) * | 1994-06-15 | 1999-09-28 | Dumex-Alpharma A/S | Pharmaceutical multiple unit particulate formulation in the form of coated cores |
US5460826A (en) | 1994-06-27 | 1995-10-24 | Alza Corporation | Morphine therapy |
GB9414699D0 (en) | 1994-07-21 | 1994-09-07 | Slagel David | Aqueous foamable composition |
US5616601A (en) | 1994-07-28 | 1997-04-01 | Gd Searle & Co | 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation |
US5521213A (en) | 1994-08-29 | 1996-05-28 | Merck Frosst Canada, Inc. | Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 |
US5593994A (en) | 1994-09-29 | 1997-01-14 | The Dupont Merck Pharmaceutical Company | Prostaglandin synthase inhibitors |
US5866154A (en) * | 1994-10-07 | 1999-02-02 | The Dupont Merck Pharmaceutical Company | Stabilized naloxone formulations |
GB9422154D0 (en) | 1994-11-03 | 1994-12-21 | Euro Celtique Sa | Pharmaceutical compositions and method of producing the same |
US5965161A (en) * | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
EP1609477B1 (en) | 1994-12-12 | 2011-11-09 | Omeros Corporation | Irrigation solution and use thereof for the perioperative inhibition of pain/inflammation and/or spasm at a vascular structure |
GB9426102D0 (en) | 1994-12-23 | 1995-02-22 | Merck Sharp & Dohme | Pharmacuetical compositions |
US5692500A (en) | 1995-01-09 | 1997-12-02 | Gaston-Johansson; Fannie | Pain measurement and recording tool and method |
US5552422A (en) | 1995-01-11 | 1996-09-03 | Merck Frosst Canada, Inc. | Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents |
US5578725A (en) | 1995-01-30 | 1996-11-26 | Regents Of The University Of Minnesota | Delta opioid receptor antagonists |
US20020006964A1 (en) * | 1995-05-16 | 2002-01-17 | Young James W. | Methods of using and compositions comprising (+) sibutramine optionally in combination with other pharmacologically active compounds |
US5510368A (en) | 1995-05-22 | 1996-04-23 | Merck Frosst Canada, Inc. | N-benzyl-3-indoleacetic acids as antiinflammatory drugs |
US5604253A (en) | 1995-05-22 | 1997-02-18 | Merck Frosst Canada, Inc. | N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors |
US5639780A (en) | 1995-05-22 | 1997-06-17 | Merck Frosst Canada, Inc. | N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors |
DE69632569T2 (de) | 1995-06-09 | 2005-08-18 | Euroceltique S.A. | Formulierungen und verfahren für eine verlängerte lokalanästhesie |
US5931809A (en) | 1995-07-14 | 1999-08-03 | Depotech Corporation | Epidural administration of therapeutic compounds with sustained rate of release |
GB9517062D0 (en) * | 1995-08-18 | 1995-10-25 | Scherer Ltd R P | Pharmaceutical compositions |
GB9517883D0 (en) | 1995-09-01 | 1995-11-01 | Euro Celtique Sa | Improved pharmaceutical ion exchange resin composition |
GB9519363D0 (en) | 1995-09-22 | 1995-11-22 | Euro Celtique Sa | Pharmaceutical formulation |
US5811126A (en) | 1995-10-02 | 1998-09-22 | Euro-Celtique, S.A. | Controlled release matrix for pharmaceuticals |
AUPN603895A0 (en) | 1995-10-19 | 1995-11-09 | University Of Queensland, The | Production of analgesic synergy by co-administration of sub-analgesic doses of two strong opioids |
US5998434A (en) | 1995-12-06 | 1999-12-07 | Eli Lilly And Company | Composition for treating pain |
ES2200158T3 (es) | 1996-03-08 | 2004-03-01 | Nycomed Danmark Aps | Cmpuesto de dosificacion de unidades multiples, de liberacion modificada. |
DK0914097T3 (da) | 1996-03-12 | 2002-04-29 | Alza Corp | Sammensætning og doseringsform omfattende opioid antagonist |
US6103258A (en) | 1996-04-12 | 2000-08-15 | Simon; David Lew | Salts and bases of the 17-(Cyclopropylmethyl)-4,5 alpha-epoxy-6-Methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opioid analgesics |
AU2676297A (en) * | 1996-04-17 | 1997-11-07 | Neurocrine Biosciences, Inc. | Ligand inhibitors of insulin-like growth factor binding proteins and methods of use therefor |
AU3404997A (en) * | 1996-05-31 | 1998-01-05 | Euro-Celtique S.A. | Sustained release oxycodone formulations with no fed/fast effect |
WO1998024412A2 (en) * | 1996-12-05 | 1998-06-11 | The Board Of Trustees Of The University Of Illinois | Compounds useful against diseases of the colon and methods for orally administering same |
DE19651551C2 (de) | 1996-12-11 | 2000-02-03 | Klinge Co Chem Pharm Fab | Opioidantagonisthaltige galenische Formulierung |
DE29719704U1 (de) | 1997-02-14 | 1998-01-22 | Gödecke AG, 10587 Berlin | Stabile Zubereitungen von Naloxonhydrochlorid |
SK282549B6 (sk) | 1997-02-14 | 2002-10-08 | G�decke Aktiengesellschaft | Spôsob stabilizácie naloxonhydrochloridu |
US5968547A (en) | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
DE19710008A1 (de) | 1997-03-12 | 1998-09-17 | Basf Ag | Feste, mindestens zweiphasige Zubereitungsformen eines Opioid-Analgeticums mit verzögerter Freisetzung |
US5780479A (en) | 1997-04-04 | 1998-07-14 | Regents Of The University Of Minnesota | Use of opioid antagonists to treat impulse-control disorders |
US6207142B1 (en) * | 1997-04-14 | 2001-03-27 | Janssen Pharmaceutica N.V. | Compositions containing an antifungal and a cationic agent |
EP1009387B1 (en) * | 1997-07-02 | 2006-04-12 | Euro-Celtique S.A. | Stabilized sustained release tramadol formulations |
WO1999005960A1 (en) | 1997-07-30 | 1999-02-11 | Universite De Montreal | Portable and programmable interactive visual analogue scale data-logger device |
ATE510542T1 (de) | 1997-09-04 | 2011-06-15 | Novoneuron Inc | Noribogain zur behandlung von schmerzen und drogenabhängigkeit |
US5972954A (en) | 1997-11-03 | 1999-10-26 | Arch Development Corporation | Use of methylnaltrexone and related compounds |
US6274591B1 (en) | 1997-11-03 | 2001-08-14 | Joseph F. Foss | Use of methylnaltrexone and related compounds |
ATE210983T1 (de) | 1997-11-03 | 2002-01-15 | Stada Arzneimittel Ag | Stabilisiertes kombinationsarzneimittel enthaltend naloxone und ein opiatanalgetikum |
CN1204890C (zh) | 1997-12-22 | 2005-06-08 | 欧罗赛铁克股份有限公司 | 防止阿片样物质滥用的方法 |
US6375957B1 (en) | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
CA2314893C (en) | 1997-12-22 | 2005-09-13 | Euro-Celtique, S.A. | Opioid agonist/antagonist combinations |
BR9908953A (pt) * | 1998-03-27 | 2000-12-05 | Upjohn Co | Utilização de cabergolina no tratamento da sìndrome de pernas agitadas (sìndrome de ekbom) |
US5957459A (en) | 1998-04-27 | 1999-09-28 | Chae; Myung Joo | Banking card game |
EP0960619B1 (de) | 1998-05-28 | 2004-03-10 | Krewel Meuselbach GmbH | Retardiertes Schmerzmittel enthaltend Tilidin |
DE19857766A1 (de) | 1998-05-28 | 1999-12-02 | Krewel Meuselbach Gmbh | Retardiertes Schmerzmittel enthaltend Tilidin |
DE29818454U1 (de) | 1998-10-15 | 1999-01-14 | Euroceltique S.A., Luxemburg/Luxembourg | Opioid-Analgetikum |
SE9803760D0 (sv) | 1998-11-04 | 1998-11-04 | Jan Hedner | Sätt att behandla och diagnostisera syndromet restless legs och motsvarande medel |
FR2787715B1 (fr) | 1998-12-23 | 2002-05-10 | Synthelabo | Composition pharmaceutique comprenant un compose hypnotique ou un de ses sels pharmaceutiquement acceptables |
DE19859636A1 (de) * | 1998-12-23 | 2000-06-29 | Hexal Ag | Kontrolliert freisetzende pharmazeutische Zusammensetzung mit Tilidinmesylat als Wirkstoff |
DE19901085C2 (de) | 1999-01-14 | 2003-12-18 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit einer selbstklebenden Matrix, enthaltend organische Säure-Additionssalze von Alkaloiden des Morphin- bzw. Morphinantyps |
US6194382B1 (en) | 1999-03-03 | 2001-02-27 | Albert Einstein College Of Medicine Of Yeshiva University | Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists |
DE19918325A1 (de) | 1999-04-22 | 2000-10-26 | Euro Celtique Sa | Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion |
US6765010B2 (en) | 1999-05-06 | 2004-07-20 | Pain Therapeutics, Inc. | Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects |
US20030178031A1 (en) * | 1999-05-07 | 2003-09-25 | Du Pen, Inc. | Method for cancer pain treatment |
US6419595B1 (en) | 1999-07-09 | 2002-07-16 | Bridgestone Sports Co., Ltd. | Solid golf ball |
US6451007B1 (en) | 1999-07-29 | 2002-09-17 | Dale E. Koop | Thermal quenching of tissue |
US20030118641A1 (en) * | 2000-07-27 | 2003-06-26 | Roxane Laboratories, Inc. | Abuse-resistant sustained-release opioid formulation |
DE19938823A1 (de) | 1999-08-19 | 2001-02-22 | Boehringer Ingelheim Pharma | Medikamentöse Behandlung des Restless Leg Syndroms |
US6258042B1 (en) * | 1999-09-17 | 2001-07-10 | James S. Factor | Visual analog scale and method of use for the diagnosis and/or treatment of physical pain |
US6451806B2 (en) | 1999-09-29 | 2002-09-17 | Adolor Corporation | Methods and compositions involving opioids and antagonists thereof |
CZ299726B6 (cs) * | 1999-11-01 | 2008-11-05 | Lécivo pro lécení zácpy a syndromu dráždivého tracníku | |
ES2278647T3 (es) | 1999-11-29 | 2007-08-16 | Adolor Corporation | Nuevos procedimientos y composiciones que comprenden opioides y antagonistas de opioides. |
WO2001052851A1 (en) | 2000-01-22 | 2001-07-26 | Albert Shulman | Methods for the treatment of substance abuse |
BR0108379A (pt) | 2000-02-08 | 2002-11-05 | Euro Celtique Sa | Composições de liberação controlada contendo agonista e antagonista opióide, método para a preparação de uma formulação em dosagem de analgésico opióide de liberação controlada com potência analgésica aumentada e sistema de administração através da derme para um analgésico opióide |
US6716449B2 (en) * | 2000-02-08 | 2004-04-06 | Euro-Celtique S.A. | Controlled-release compositions containing opioid agonist and antagonist |
WO2001068080A2 (en) | 2000-03-15 | 2001-09-20 | Wolfgang Sadee | Neutral antagonists and use thereof in treating drug abuse |
EP1284736A2 (en) | 2000-05-05 | 2003-02-26 | Pain Therapeutics, Inc. | Opioid antagonist compositions and dosage forms |
AU5956001A (en) | 2000-05-05 | 2001-11-20 | Pain Therapeutics Inc | Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists |
AU2001268353A1 (en) | 2000-06-09 | 2001-12-17 | The Regents Of The University Of California | Method of treating pain using nalbuphine and opioid antagonists |
US7223421B2 (en) * | 2000-06-30 | 2007-05-29 | Mcneil-Ppc, Inc. | Teste masked pharmaceutical particles |
GB0026137D0 (en) | 2000-10-25 | 2000-12-13 | Euro Celtique Sa | Transdermal dosage form |
AR031152A1 (es) * | 2000-10-31 | 2003-09-10 | Upjohn Co | Tratamientos nuevos para el sindrome de piernas inquietas |
CA2444053C (en) * | 2001-04-19 | 2008-06-17 | Warner-Lambert Company Llc | Fused bicyclic or tricyclic amino acids |
UA81224C2 (uk) | 2001-05-02 | 2007-12-25 | Euro Celtic S A | Дозована форма оксикодону та її застосування |
DE60238756D1 (de) | 2001-05-11 | 2011-02-10 | Endo Pharmaceuticals Inc | Opioid enthaltende arzneiform gegen missbrauch |
CA2778114A1 (en) * | 2001-05-11 | 2002-11-21 | Endo Pharmaceuticals, Inc. | Abuse-resistant opioid dosage form |
DE10131113A1 (de) | 2001-06-28 | 2003-01-23 | Siemens Linear Motor Systems G | Rotations-Elektromotor |
WO2003004009A1 (en) | 2001-07-02 | 2003-01-16 | Geneva Pharmaceuticals, Inc. | Pharmaceutical composition |
AU2002316738B2 (en) * | 2001-07-18 | 2009-01-08 | Euro-Celtique S.A. | Pharmaceutical combinations of oxycodone and naloxone |
WO2003013433A2 (en) | 2001-08-06 | 2003-02-20 | Euro-Celtique S.A. | Sequestered antagonist formulations |
US7144587B2 (en) * | 2001-08-06 | 2006-12-05 | Euro-Celtique S.A. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent |
US20030044458A1 (en) | 2001-08-06 | 2003-03-06 | Curtis Wright | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
US7332182B2 (en) * | 2001-08-06 | 2008-02-19 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant |
BR0212020A (pt) | 2001-08-06 | 2005-08-16 | Euro Celtique Sa | Formas de dosagem, métodos para impedir o abuso de uma forma de dosagem, métodos para impedir o desvio de uma forma de dosagem, métodos para o tratamento de dor e método de preparação de uma forma de dosagem |
HUP0401191A3 (en) | 2001-08-06 | 2006-11-28 | Euro Celtique Sa | Opioid agonist formulations with releasable and sequestered antagonist and process for their preparation |
KR20040060917A (ko) | 2001-08-06 | 2004-07-06 | 유로-셀티크 소시에떼 아노뉨 | 오피오이드 남용을 방지하기 위한 조성물 및 방법 |
ATE426429T1 (de) | 2001-09-06 | 2009-04-15 | Hans Gregersen | Ballonkathetersystem zur stimulation und messung der durch stimuli erzeugten reaktion |
EP2957281A1 (en) * | 2001-09-21 | 2015-12-23 | Egalet Ltd. | Polymer release system |
US20040253310A1 (en) * | 2001-09-21 | 2004-12-16 | Gina Fischer | Morphine polymer release system |
US20030092759A1 (en) * | 2001-09-24 | 2003-05-15 | Abuzzahab Faruk S. | Anticonvulsant derivatives useful for the treatment of restless limb syndrome and periodic limb movement disorder |
WO2003073937A1 (en) | 2002-03-06 | 2003-09-12 | Euro-Celtique S.A. | Analog scale for measuring pain |
CA2478558C (en) | 2002-03-14 | 2012-09-11 | Euro-Celtique, S.A. | Naltrexone hydrochloride compositions |
EP1492506B2 (en) | 2002-04-05 | 2016-06-29 | Euro-Celtique S.A. | Matrix for sustained, invariant and independent release of active compounds |
DE10215131A1 (de) | 2002-04-05 | 2003-10-16 | Euro Celtique Sa | Matrix zur verzögerten, gleichbleibenden und unabhängigen Freisetzung von Wirkstoffen |
DE10215067A1 (de) | 2002-04-05 | 2003-10-16 | Euro Celtique Sa | Lagerstabiles pharmazeutisches Präparat, das Oxycodon und Naloxon umfasst |
US20030191147A1 (en) * | 2002-04-09 | 2003-10-09 | Barry Sherman | Opioid antagonist compositions and dosage forms |
EP1364649A1 (en) | 2002-05-23 | 2003-11-26 | Cilag AG | Adduct of topiramate and tramadol hydrochioride and uses thereof |
US7399488B2 (en) * | 2002-07-05 | 2008-07-15 | Collegium Pharmaceutical, Inc. | Abuse-deterrent pharmaceutical compositions of opiods and other drugs |
RU2222260C1 (ru) | 2002-07-08 | 2004-01-27 | Сибирский государственный медицинский университет | Способ дифференцированной оценки степени функциональной активности тонкой кишки |
JP5189242B2 (ja) | 2002-09-23 | 2013-04-24 | アルケルメス ファーマ アイルランド リミテッド | 乱用抵抗性の医薬組成物 |
CN100500130C (zh) | 2003-01-23 | 2009-06-17 | 株式会社太平洋 | 缓释制剂及其制备方法 |
DK2368554T3 (en) | 2003-04-08 | 2015-01-26 | Progenics Pharm Inc | A pharmaceutical composition comprising methylnaltrexone |
TWI357815B (en) | 2003-06-27 | 2012-02-11 | Euro Celtique Sa | Multiparticulates |
US20050053659A1 (en) | 2003-09-10 | 2005-03-10 | Pace Gary W. | Methods and compositions for reducing the risk associated with the administration of opioid analgesics in patients with diagnosed or undiagnosed respiratory illness |
TWI350762B (en) | 2004-02-12 | 2011-10-21 | Euro Celtique Sa | Particulates |
US7700626B2 (en) * | 2004-06-04 | 2010-04-20 | Adolor Corporation | Compositions containing opioid antagonists |
EP1604667A1 (en) | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioids for the treatment of the restless leg syndrome |
EP1604666A1 (en) | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD) |
GB2418854B (en) | 2004-08-31 | 2009-12-23 | Euro Celtique Sa | Multiparticulates |
AU2006208627B8 (en) | 2005-01-28 | 2009-08-13 | Mundipharma Pty Limited | Alcohol resistant dosage forms |
EP1702558A1 (en) | 2005-02-28 | 2006-09-20 | Euro-Celtique S.A. | Method and device for the assessment of bowel function |
EP1695700A1 (en) | 2005-02-28 | 2006-08-30 | Euro-Celtique S.A. | Dosage form containing oxycodone and naloxone |
US20070092576A1 (en) | 2005-10-20 | 2007-04-26 | Adolor Corporation | Compositions containing opioid antagonists |
EP1813276A1 (en) | 2006-01-27 | 2007-08-01 | Euro-Celtique S.A. | Tamper resistant dosage forms |
US20070185145A1 (en) | 2006-02-03 | 2007-08-09 | Royds Robert B | Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same |
WO2007111945A2 (en) | 2006-03-22 | 2007-10-04 | Trustees Of Boston University | Method for management of diarrhea |
AU2007240873A1 (en) | 2006-04-19 | 2007-11-01 | Jill P. Smith | Treatment of inflammatory and ulcerative diseases of the bowel with opioid antagonists |
DE202006018609U1 (de) | 2006-08-29 | 2007-05-16 | Euro-Celtique S.A. | Verwendung von Opioidformulierungen in nadellosen Vorrichtungen zur Medikamentenverabreichung |
TW200817048A (en) | 2006-09-08 | 2008-04-16 | Wyeth Corp | Dry powder compound formulations and uses thereof |
EP2042176A1 (en) | 2007-09-26 | 2009-04-01 | Euro-Celtique S.A. | Use of a combination of an opioid agonist and an opioid antagonist for the treatment of Crohn's disease |
CN105456267A (zh) | 2008-07-07 | 2016-04-06 | 欧洲凯尔特公司 | 阿片类拮抗剂治疗尿潴留的用途 |
MX347106B (es) | 2009-03-10 | 2017-04-12 | Euro-Celtique S A * | Coposiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona. |
NO330672B1 (no) | 2009-11-12 | 2011-06-06 | Proxdynamics As | Rotormekanisme for helikoptere |
WO2012020097A2 (en) | 2010-08-13 | 2012-02-16 | Euro-Celtique S.A. | Use of binders for manufacturing storage stable formulations |
-
2003
- 2003-04-04 EP EP03720425.2A patent/EP1492506B2/en not_active Expired - Lifetime
- 2003-04-04 EP EP11177516.9A patent/EP2425824B1/en not_active Revoked
- 2003-04-04 DK DK03720425.2T patent/DK1492506T4/en active
- 2003-04-04 MX MXPA04009714A patent/MXPA04009714A/es active IP Right Grant
- 2003-04-04 DE DE17169621.4T patent/DE17169621T1/de active Pending
- 2003-04-04 DE DE20308436U patent/DE20308436U1/de not_active Expired - Lifetime
- 2003-04-04 JP JP2003581744A patent/JP4620355B2/ja not_active Expired - Fee Related
- 2003-04-04 US US10/510,674 patent/US20050245556A1/en not_active Abandoned
- 2003-04-04 TW TW092107765A patent/TWI334779B/zh not_active IP Right Cessation
- 2003-04-04 EP EP10180495A patent/EP2308474A1/en not_active Withdrawn
- 2003-04-04 SI SI200332523A patent/SI2425824T1/sl unknown
- 2003-04-04 EP EP11177518.5A patent/EP2425821B1/en not_active Revoked
- 2003-04-04 TW TW092107773A patent/TWI337077B/zh not_active IP Right Cessation
- 2003-04-04 KR KR1020067027164A patent/KR100784341B1/ko active IP Right Grant
- 2003-04-04 EP EP17169621.4A patent/EP3326618A1/en not_active Withdrawn
- 2003-04-04 CA CA002478523A patent/CA2478523A1/en not_active Abandoned
- 2003-04-04 DK DK11177516.9T patent/DK2425824T5/en active
- 2003-04-04 EP EP11177520.1A patent/EP2425825B9/en not_active Revoked
- 2003-04-04 AT AT03720425T patent/ATE418967T2/de active
- 2003-04-04 CN CNB038071770A patent/CN100411611C/zh not_active Expired - Lifetime
- 2003-04-04 DE DE17154462.0T patent/DE17154462T1/de active Pending
- 2003-04-04 PT PT111775185T patent/PT2425821T/pt unknown
- 2003-04-04 CN CN201710521042.3A patent/CN107669681A/zh active Pending
- 2003-04-04 ES ES17154462T patent/ES2733051T1/es active Pending
- 2003-04-04 EP EP05020580A patent/EP1639997A1/en not_active Withdrawn
- 2003-04-04 EP EP10180496A patent/EP2316428A1/en not_active Withdrawn
- 2003-04-04 ES ES11177516.9T patent/ES2627298T3/es not_active Expired - Lifetime
- 2003-04-04 ES ES11177520.1T patent/ES2608006T3/es not_active Expired - Lifetime
- 2003-04-04 GE GEAP8488A patent/GEP20064022B/en unknown
- 2003-04-04 HU HUE11177520A patent/HUE031668T2/en unknown
- 2003-04-04 ES ES03720424.5T patent/ES2546010T3/es not_active Expired - Lifetime
- 2003-04-04 GE GEAP20038488A patent/GEP20074022B/en unknown
- 2003-04-04 EP EP20100176720 patent/EP2319496A1/en not_active Withdrawn
- 2003-04-04 DE DE60325567T patent/DE60325567D1/de not_active Expired - Lifetime
- 2003-04-04 WO PCT/EP2003/003540 patent/WO2003084520A2/en active Application Filing
- 2003-04-04 RU RU2004131870/15A patent/RU2295344C2/ru active
- 2003-04-04 LT LTEP11177518.5T patent/LT2425821T/lt unknown
- 2003-04-04 PT PT111775201T patent/PT2425825T/pt unknown
- 2003-04-04 CN CN038077965A patent/CN1646102B/zh not_active Expired - Lifetime
- 2003-04-04 DE DE20321531U patent/DE20321531U1/de not_active Expired - Lifetime
- 2003-04-04 AU AU2003224041A patent/AU2003224041B2/en not_active Expired
- 2003-04-04 BR BR0309004-3A patent/BR0309004A/pt not_active Application Discontinuation
- 2003-04-04 PT PT03720425T patent/PT1492506E/pt unknown
- 2003-04-04 LT LTEP11177520.1T patent/LT2425825T/lt unknown
- 2003-04-04 EP EP10160827A patent/EP2243471A1/en not_active Withdrawn
- 2003-04-04 SI SI200332440T patent/SI1492505T1/sl unknown
- 2003-04-04 AP APAP/P/2004/003138A patent/AP2397A/en active
- 2003-04-04 EP EP10180498A patent/EP2316429A1/en not_active Withdrawn
- 2003-04-04 EP EP11177513A patent/EP2425823A1/en not_active Withdrawn
- 2003-04-04 GE GEAP8489A patent/GEP20084485B/en unknown
- 2003-04-04 DK DK11177520.1T patent/DK2425825T3/en active
- 2003-04-04 RU RU2004130845/15A patent/RU2297225C2/ru active
- 2003-04-04 PT PT37204245T patent/PT1492505E/pt unknown
- 2003-04-04 BR BRPI0309544A patent/BRPI0309544B8/pt not_active IP Right Cessation
- 2003-04-04 HU HUE03720424A patent/HUE027004T2/en unknown
- 2003-04-04 KR KR1020047015830A patent/KR100717591B1/ko active IP Right Grant
- 2003-04-04 HU HUE11177516A patent/HUE032656T2/en unknown
- 2003-04-04 DE DE20308437U patent/DE20308437U1/de not_active Expired - Lifetime
- 2003-04-04 MX MXPA04009713A patent/MXPA04009713A/es active IP Right Grant
- 2003-04-04 CN CN2012102169087A patent/CN102813654A/zh active Pending
- 2003-04-04 WO PCT/EP2003/003541 patent/WO2003084504A2/en active Application Filing
- 2003-04-04 ES ES03720425.2T patent/ES2320748T5/es not_active Expired - Lifetime
- 2003-04-04 EP EP05020579A patent/EP1639996A1/en not_active Withdrawn
- 2003-04-04 CA CA2478515A patent/CA2478515C/en not_active Expired - Lifetime
- 2003-04-04 EP EP10176078A patent/EP2308475A1/en not_active Withdrawn
- 2003-04-04 AU AU2003224040A patent/AU2003224040B2/en not_active Expired
- 2003-04-04 EP EP17154462.0A patent/EP3241548A1/en not_active Withdrawn
- 2003-04-04 EP EP10180494A patent/EP2311438A1/en not_active Withdrawn
- 2003-04-04 SI SI200332524A patent/SI2425821T1/sl unknown
- 2003-04-04 TW TW095133492A patent/TWI345973B/zh not_active IP Right Cessation
- 2003-04-04 ES ES17169621T patent/ES2733044T1/es active Pending
- 2003-04-04 ES ES11177518.5T patent/ES2627300T3/es not_active Expired - Lifetime
- 2003-04-04 NZ NZ535286A patent/NZ535286A/en not_active IP Right Cessation
- 2003-04-04 JP JP2003581760A patent/JP4755810B2/ja not_active Expired - Fee Related
- 2003-04-04 US US10/510,673 patent/US20050245483A1/en not_active Abandoned
- 2003-04-04 HU HUE11177518A patent/HUE032529T2/en unknown
- 2003-04-04 LT LTEP11177516.9T patent/LT2425824T/lt unknown
- 2003-04-04 AP APAP/P/2004/003137A patent/AP2043A/en active
- 2003-04-04 PT PT111775169T patent/PT2425824T/pt unknown
- 2003-04-04 DK DK03720424.5T patent/DK1492505T3/en active
- 2003-04-04 KR KR10-2004-7015828A patent/KR20040098050A/ko not_active Application Discontinuation
- 2003-04-04 IL IL16399003A patent/IL163990A0/xx unknown
- 2003-04-04 CA CA2708900A patent/CA2708900C/en not_active Expired - Fee Related
- 2003-04-04 SI SI200331518T patent/SI1492506T1/sl unknown
- 2003-04-04 SI SI200332513A patent/SI2425825T1/sl unknown
- 2003-04-04 DK DK11177518.5T patent/DK2425821T5/en active
- 2003-04-04 EP EP03720424.5A patent/EP1492505B1/en not_active Revoked
- 2003-04-07 AR ARP030101200A patent/AR039378A1/es not_active Application Discontinuation
- 2003-04-07 AR ARP030101201A patent/AR039379A1/es not_active Application Discontinuation
-
2004
- 2004-09-09 IL IL16398904A patent/IL163989A0/xx unknown
- 2004-09-09 IL IL163990A patent/IL163990A/en active IP Right Grant
- 2004-09-10 ZA ZA2004/07267A patent/ZA200407267B/en unknown
- 2004-09-13 ZA ZA2004/07317A patent/ZA200407317B/en unknown
- 2004-09-23 CO CO04094961A patent/CO5611100A2/es not_active Application Discontinuation
- 2004-09-24 CO CO04095278A patent/CO5611093A2/es not_active Application Discontinuation
- 2004-10-04 TN TNP2004000192A patent/TNSN04192A1/fr unknown
- 2004-11-03 MA MA27929A patent/MA27116A1/fr unknown
- 2004-11-03 MA MA27928A patent/MA27249A1/fr unknown
-
2005
- 2005-06-15 HK HK12107145.5A patent/HK1166463A1/zh not_active IP Right Cessation
- 2005-06-15 HK HK05105025.3A patent/HK1072367A1/xx not_active IP Right Cessation
- 2005-06-15 HK HK05105024.4A patent/HK1072366A1/xx not_active IP Right Cessation
-
2006
- 2006-08-08 RU RU2006128796/15A patent/RU2342935C2/ru active
-
2007
- 2007-04-23 IL IL182742A patent/IL182742A0/en unknown
- 2007-08-17 FI FI20070322U patent/FI7846U1/fi not_active IP Right Cessation
- 2007-09-18 DK DK200700243U patent/DK200700243U3/da not_active IP Right Cessation
-
2009
- 2009-03-13 JP JP2009061144A patent/JP5107954B2/ja not_active Expired - Lifetime
- 2009-03-23 CY CY20091100346T patent/CY1108914T1/el unknown
- 2009-08-27 IL IL200621A patent/IL200621A/en active IP Right Grant
-
2010
- 2010-04-06 JP JP2010088165A patent/JP5932209B2/ja not_active Expired - Lifetime
-
2011
- 2011-09-30 US US13/251,172 patent/US20120108621A1/en not_active Abandoned
-
2012
- 2012-01-11 US US13/348,617 patent/US8846090B2/en not_active Expired - Lifetime
-
2013
- 2013-04-15 AR ARP130101201A patent/AR090677A2/es not_active Application Discontinuation
- 2013-10-18 US US14/058,108 patent/US8846091B2/en not_active Expired - Lifetime
- 2013-10-18 US US14/058,068 patent/US20140045877A1/en not_active Abandoned
-
2014
- 2014-03-04 JP JP2014041261A patent/JP2014129397A/ja active Pending
- 2014-06-16 US US14/305,785 patent/US9555000B2/en not_active Expired - Lifetime
- 2014-09-17 US US14/489,452 patent/US9655855B2/en not_active Expired - Lifetime
-
2015
- 2015-08-25 CY CY20151100735T patent/CY1116640T1/el unknown
-
2017
- 2017-01-05 US US15/399,487 patent/US9907793B2/en not_active Expired - Lifetime
- 2017-02-07 CY CY20171100165T patent/CY1118921T1/el unknown
- 2017-04-28 US US15/582,119 patent/US20170231978A1/en not_active Abandoned
- 2017-06-22 CY CY20171100665T patent/CY1119120T1/el unknown
- 2017-06-28 CY CY20171100683T patent/CY1119168T1/el unknown
-
2018
- 2018-01-26 US US15/881,459 patent/US10420762B2/en not_active Expired - Lifetime
- 2018-05-03 HK HK18105703.7A patent/HK1246176A1/zh unknown
- 2018-06-25 PH PH12018000176A patent/PH12018000176A1/en unknown
- 2018-09-11 HK HK18111654.4A patent/HK1254279A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1119168T1 (el) | Φαρμακευτικο παρασκευασμα που περιεχει οξυκωδονη και ναλοξονη | |
CY1117656T1 (el) | Επιλογες θεραπειας για τη νοσο του fabry | |
CY1118206T1 (el) | Φαρμακευτικη συνθεση για δερματικη χρηση για να θεραπευεται ψωριαση που περιλαμβανει καλσιποτριολη και βηταμεθαζονη | |
CY1106386T1 (el) | Υποκατεστημενα παραγωγα 3-πυρρολιδιν-ινδολης | |
CY1114139T1 (el) | Πλακιδιο βουπρενορφινης για τη θεραπεια υποκαταστασης ναρκωτικων | |
CY1113116T1 (el) | Υποκατεστημενες 4-αμινοκυκλοεξανολες | |
CY1111613T1 (el) | Μεθοδοι για την αντιμετωπιση της μολυνσης απο hiv | |
CY1107682T1 (el) | Παραγωγα 4-τετραζολυλ-4 φαινυλπιπεριδινης για θεραπεια πονου | |
CY1106468T1 (el) | Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης | |
CY1107383T1 (el) | Αναστολεις της φωσφολιπασης α2 του κυτοπλασμικου διαλυματος | |
DE50310516D1 (de) | Fredericamycin-derivate | |
CY1109361T1 (el) | Υποκατεστημενες 4-αμινοκυκλοεξανολες | |
DK1781277T3 (da) | Kombinationssammensætning, der omfatter Ibuprofen og Paracetamol | |
ATE260650T1 (de) | Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac | |
CY1109229T1 (el) | Χρηση σπογγοσινης (2-μεθοξυαδενοσινης) για τη θεραπεια πονου, συγκεκριμενα υπερευαισθησιας στο πονο | |
CY1111698T1 (el) | Συνδυασμος που περιλαμβανει εναν ανταγωνιστη υποδοχεα ατ1 και εναν ενισχυτη εκκρισης ινσουλινης ή εναν ευαισθητοποιητη ινσουλινης | |
CY1111541T1 (el) | Αγωνιστες β-2 αδρενοϋποδοχεα για την αγωγη παθησεων συνδετικου ιστου του δερματος | |
CY1110162T1 (el) | Φαρμακοτεχνικη μορφη και μεθοδοι για την αγωγη της θρομβοκυτταραιμιας | |
CY1106845T1 (el) | Χρηση της φλουμαζενιλης για την παρασκευη ενος φαρμακου για την αγωγη της εξαρτησεως απο την κοκαϊνη | |
CY1109221T1 (el) | Χιμαιρικο γονιδιο που κωδικοποιει τους αντιγονικους καθοριστες τεσσαρων πρωτεϊνων του l. infantum | |
CY1113959T1 (el) | Χρηση λιποσωματων pvp-ιωδιου για θεραπεια ακμης | |
DE60123100D1 (de) | Honig enthaltende pharmazeutische zusammensetzung zur wundbehandlung | |
CY1107231T1 (el) | Υποκατεστημενα παραγωγα 4-αμινοκυκλοεξανολης | |
CY1105317T1 (el) | Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων | |
IS7492A (is) | Lyfjablöndu uppskriftir, sem innifela melantónín |